IPO on Nasdaq First North
Important Notice
You have selected a website with information that is not intended to be published, published or distributed, directly or indirectly, in or to the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa. By clicking "Yes, I accept" below, you accept the terms of access to this website.
The offer to subscribe for shares in Newbury Pharmaceuticals AB (publ) in accordance with the terms of the prospectus is not directed at persons whose participation in the offer requires additional prospectuses, registration measures or other measures than those that follow from Swedish law. The prospectus and other documents relating to the offer may not be distributed in any country where such distribution or the offer requires further measures than those stated in the previous sentence or is contrary to rules in such country. Newly issued shares have not been registered and will not be registered in accordance with the United States Securities Act of 1933 as amended, or in accordance with applicable law in Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa and may not be offered or transferred. directly or indirectly, to a person domiciled in one of these countries. Notification of subscription for shares in violation of the above may be considered invalid and disregarded.
Disputes in connection with the offer, the content of the prospectus and related legal matters shall be decided by a Swedish court exclusively. Swedish law is exclusively applicable to the prospectus and to the offer according to the prospectus. In order to be entitled to access the information on the following website, you must be deemed, if you access the following website, to have confirmed and agreed that (i) you have read and accept the terms and restrictions set out above and (ii) you are not in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa.
The offer to subscribe for shares in Newbury Pharmaceuticals AB (publ) in accordance with the terms of the prospectus is not directed at persons whose participation in the offer requires additional prospectuses, registration measures or other measures than those that follow from Swedish law. The prospectus and other documents relating to the offer may not be distributed in any country where such distribution or the offer requires further measures than those stated in the previous sentence or is contrary to rules in such country. Newly issued shares have not been registered and will not be registered in accordance with the United States Securities Act of 1933 as amended, or in accordance with applicable law in Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa and may not be offered or transferred. directly or indirectly, to a person domiciled in one of these countries. Notification of subscription for shares in violation of the above may be considered invalid and disregarded.
Disputes in connection with the offer, the content of the prospectus and related legal matters shall be decided by a Swedish court exclusively. Swedish law is exclusively applicable to the prospectus and to the offer according to the prospectus. In order to be entitled to access the information on the following website, you must be deemed, if you access the following website, to have confirmed and agreed that (i) you have read and accept the terms and restrictions set out above and (ii) you are not in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa.
© 2021, Newbury Pharmaceuticals AB